Introduction
Reverse transcription is an essential step in the HIV Iifecycle, and consequently reverse transcriptase (RT) is a well-studied therapeutic target. The compounds that inhibit RT fall broadly into two categories; nucleoside analogues and non-nucleoside inhibitors (Baba et al., 1991; Goldman et al., 1991; Balzarini et al., 1992; Merluzzi et aI., 1990; Romero et al., 1991; De Clercq, 1992; Grab et al., 1992; Pauwels et al., 1990; Tramontano and Cheng, 1992) . A common feature of the non-nucleoside RT inhibitors is the rapid emergence of drug-resistant HIV-1 mutants after passage of virus in cell culture in the presence of these compounds (Richman et al., 1991; Nunberg et al., 1991; Mellors et al., 1993) . Clinically, emergence of drug resistance also occurs rapidly, in about one month (Richman 1993) . Genetic analysis indicates that the reverse transcriptase of these HIV-1 variants contains different amino acid substitutions depending on the class of non-nucleoside RT inhibitor. To date, the following amino acid alterations have been described: pyridinone (K103N, Y181C) (Nunberg et aI., 1991; Balzarini et al., 1992) , TSAO-T (E138K) (Balzariniet al., 1992) , Nevirapine (Y181C, V106A) (Richman et al., 1991; Mellors et al., 1992) , TIBO R82150 (L1001 and Y181C) (Mellors et al., 1992 (Mellors et al., , 1993 and CI-TIBO R82913 (Y181C, K103N, L100lN181 C, L100lN188H) (Larder, 1992; Balzarini et al., 1993) . In general, the HIV strains containing the RT amino acid changes E138K, L1001 or K1 03N are still sensitive to the other non-nucleoside RT inhibitors, whereas the RT amino acid mutation Y181C results in significant resistance to all classes of HIV-1-specific RT inhibitors (Balzarini et al., 1993) . In the process of studying resistance to other antiviral compounds, we included the selection of TIBO-resistant virus for comparison. Here, we report the selection of a TIBO-resistant HIV-1 RF strain together with genotypic and phenotypic analyses of mutant RTs and mutant viruses.
The wild-type (WT) HIV-1 RF strain was passaged in CEM-55 cells in the presence of increasing concentrations of R82150. Cell-free virus was used to initiate a new cycle of infection every 4 to 6 days. Concentrations of drug used in the six sequential passages were 0.2, 0.2, 0.2, 0.4, 0.6 and 1.0IlM. The drug sensitivity studies of passage 6 virus in CEM-55 cells by an XTT cell protection assay (Weislow et al., 1989 ) showed that the virus had an IC so value of 1.3IlM, which is -33-fold more resistantthan parental HIV-1 RF (ICso=0.04IlM) ( Fig. 1) . CEM-SS cells were infected with either virus in the presence of serial dilutions of R82150 and incubated for 6 days at 3loG. Viability was determined by XTT formazan production and is expressed as the percentage of formazan produced in the wells of untri-i\lted control cells.
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Further phenotypic analyses indicated that resistant virus was cross-resistant to TGG-II-23A (1,4-dimethyl-1-[5,5-dimethyl-2-oxazolonylj-naphthalen-2-one), a new structural class of NNRT inhibitor, with a >50-fold shift (>1000~M vs. 19.1~M) in IC so (Alam et al., 1993) . However, the mutant and wild-type viruses remained equally sensitive to 001, D4T, AZT and the pyrophosphate analogue PFA (data not shown).
To determine the genetic changes induced by R82150 selection, the entire RT coding region was PCR amplified (Larder and Kemp 1989) from CEM-SS cells infected with passage 6 HIV-RF virus and cloned into plasmid pGEM3Zf(-) (Promega, Madison, WI). The RT genes from 10 resistant and 5 parental clones were sequenced (Sequenase II, USB, Cleveland, OH). In comparison with the parental strain, 8 out of 10 resistant RT clones had the Y181C substitution, one had V1081rr473A changes and the other clone had L303Q/A355T mutations. We failed to observe these mutations either in our wild-type clones or in the Los Alamos HIV sequence data base. To evaluate the significance of these putative substitutions in R82150 resistance, PCR-amplified RT genes (containing mutations Y181C, V1081rr473A or L303Q/A355T) were cloned in the TT polymerase expression vector pRSET (Invitrogen, San Diego, CA). RT expression clones containing the single mutation V1081 were also generated by domain swapping. The recombinant RTs in the bacterial extract were then tested for sensitivity to R82150 and AZTtriphosphate. All the mutant and wild-type clones had similar sensitivities to AZT-triphosphate (data not shown). However, their sensitivities to R82150 differed. As shown TlBG-resistant HIV-1 279 in Fig. 2 , in the RT assay using poly(rC)/(dG) as template/primer (Johnson et el., 1990) , RT with the Y181C mutation was 15-fold more resistant to R82150. The RT with mutation V1081 also had a low level of resistance (x3) to R82150. Experiments using the poly (rA)/(dT) template/primer and RT from E. coli co-expressing HIV-protease gave similar results (data not shown). In all cases the IC so of RT with the V1081 mutation was consistently 2to 3-fold higher than that of the WT enzyme. Additional mutations L303Q and A355T did not affect the sensitivity of RTto R82150, although the mutation T473A seemed to decrease the sensitivity slightly (data not shown).
To determine whether these mutations alone conferred TIBO resistance on the virus, we introduced each of the V1081 and Y181C mutations into the proviral clone pNL4-3 by site-directed mutagenesis (Deng and Nickoloff, 1992) . The mutagenized proviral clones were transfected into Hela CD4+ cells, and the resulting viruses were examined for relative drug resistance (Soudeyns et al., 1991) in MT-2 cells using p24 antigen production as an endpoint (p24 ELISA; NEN Dupont, Boston, MA). Infectious virus containing the Y181C mutation was approximately 14-fold more resistant to R82150 than wild-type virus (IC so = 0.495 ± 0.179 and 0.035 ± 0.01~M, respectively), while virus containing the V1081 mutation was only 2-fold more resistant (IC so = 0.07 ± .025~M). No signifi- 10mM MgCI 2 , 0.5 U mr" poly rC/oligo dG, 2-, 8 , and 25 llCi mr' . RT reactions were incubated for 30 min at 3loC and terminated by addition of TCA. Precipitable counts were determined by liquid scintillation counting. E. coli extracts were prepared from 1 ml culture lysed in 0.3 mllysis buffer (500 mM NaCI, 50 mM Tris-HCI pH 8.0, 2 mM EDTA, 5mM DTT, 1 mM PMSF, 0.1 % Triton X-l00, 1 mqrnr" lysozyme, and 10 % glycerol for 5 min). Extracts were centrifuged for 10 min at full speed in a microfuge and the supernatant was either assayed directly or frozen at -lO°C. Sensitivities of wild-type RT (0) or RT with mutations 181C (L), 1081(0) and 30SQ/355T (e) are shown. cant differences in sensitivity to AZT or ddl were observed amongst these three viruses.
In summary, our data show that HIV-1 RT with either of the mutations Y181 C and V1081 has altered sensitivity to R82150 in an in vitro RT assay. Infectious HIV carrying these RT substitutions is also less susceptible to R82150, although the level of sensitivity conferred by Y181C is 6fold higher than that conferred by V1081. Thus, in addition to the previously reported R82150-associated mutations, L1001 and Y181 C, we found that the V1 081 alteration also causes a change in TIBO susceptiblity. Recently, Byrnes et al. (1993) showned that HIV containing the mutation V1081 was 3.8 times less sensitive to TIBO R83913. HIV reverse transcriptase carrying such a mutation was also found to be 2.7 times more resistant to R83913 in an in vitro assay. These values are in accordance with the level of resistance we have observed here.
